Two years post affordable medicines facility for malaria program: Availability and prices of anti-malarial drugs in central Ghana

被引：7
作者：
Freeman A. [1 ,2 ]
Kwarteng A. [2 ]
Febir L.G. [2 ]
Amenga-Etego S. [2 ]
Owusu-Agyei S. [2 ]
Asante K.P. [2 ]
机构：
[1] Georgetown University, 3700 O St NW, Washington, 20057, DC
[2] Kintampo Health Research Centre, Ghana Health Service, P.O. Box 200, Kintampo North Municipality, Brong Ahafo Region
来源：
Journal of Pharmaceutical Policy and Practice | / 10卷 / 1期
关键词：
AMFm; Artemisinin-based combination therapy; Ghana; Global fund; Kintampo; Malaria; Subsidy;
D O I：
10.1186/s40545-017-0103-0
中图分类号：
学科分类号：
摘要：
Background: The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in 8 malaria endemic countries in Africa. The WHO supervised the manufacture of the subsidized products, named them Quality Assured ACTs (QAACT) and printed a Green Leaf Logo on all QAACT packages. Ghana began to receive the subsidized QAACTs in 2010. Methods: A cross-sectional stock survey was conducted at 63 licensed chemical shops (LCS) and private pharmacies in two districts of the Brong-Ahafo region of Ghana to determine the availability and price of all anti-malarial treatments. Drug outlets were visited over a 3-weeks period in October and November of 2014, about 2 years after the end of AMFm program. Results: At least one QAACT was available in 88.9% (95% CI 80.9% - 96.8%) of all drug outlets with no difference between urban and rural locations. Non-Assured ACTs (NAACT) were significantly more available in urban drug outlets [75.0% availability (95% CI 59.1% - 90.9%)] than in rural drug outlets [16.1% availability (95% CI 2.4% - 29.9%)]. The top selling product was Artemether Lumefantrine with the Green Leaf Logo, a QAACT. There was a significant difference in the mean price of a QAACT [$1.04 USD (95% CI $0.98 - $1.11)], and the mean price of a NAACT in both the urban and rural areas [$2.46 USD (95% CI $2.11 - $2.81)]. There was no significant difference in the price of any product that was available in urban and rural settings Conclusion: About 2 years after the AMFm program, subsidized QAACTs in Ghana were widely available and more affordable than NAACTs in the Kintampo North District and Kintampo South Municipality of Ghana. The AMFm program appeared to have mostly succeeded in making QAACTs available and affordable. © 2017 The Author(s).
引用
收藏
相关论文
共 22 条
  • [1] Murray C.J.L., Ortblad K.F., Guinovart C., Lim S.S., Wolock T.M., Roberts D.A., Et al., Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet, 384, pp. 1005-1070, (2014)
  • [2] Owusu-Agyei S., Asante K.P., Adjuik M., Adjei G., Awini E., Adams M., Et al., Epidemiology of malaria in the forest-savanna transitional zone of Ghana, Malar J, 8, (2009)
  • [3] Asante K.P., Zandoh C., Dery D.B., Brown C., Adjei G., Antwi-Dadzie Y., Et al., Malaria epidemiology in the Ahafo area of Ghana, Malar J, 10, (2011)
  • [4] Azabre B.A., Teye J.K., Yaro J.A., Malaria control strategies in the Kassena-Nankana East and West Districts of Ghana, Ghana J Geogr, 5, pp. 102-120, (2014)
  • [5] Zwang J., Olliaro P., Barennes H., Bonnet M., Brasseur P., Bukirwa H., Et al., Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis, Malar J, 8, (2009)
  • [6] Maslove D.M., Mnyusiwalla A., Mills E.J., McGowan J., Attaran A., Wilson K., Barriers to the effective treatment and prevention of malaria in Africa: a systematic review of qualitative studies, BMC Int Health Hum Rights, 9, pp. 1-10, (2009)
  • [7] Ghana. Guidelines for Case Management of Malaria in Ghana, (2014)
  • [8] Goodman C., Brieger W., Unwin A., Mills A., Meek S., Greer G., Medicine sellers and malaria treatment in Sub-Saharan Africa: what do they do and how can their practice be improved?, Am J Trop Med Hyg, 77, pp. 203-218, (2007)
  • [9] Asante K.P., Abokyi L., Zandoh C., Owusu R., Awini E., Sulemana A., Et al., Community perceptions of malaria and malaria treatment behaviour in a rural district of Ghana: implications for artemisinin combination therapy, BMC Public Health, 10, pp. 1-14, (2010)
  • [10] Davis B., Ladner J., Sams K., Tekinturhan E., Korte D., Saba J., Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries, Malar J, 12, (2013)
123